sodium pentanolate | 1941-84-0

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: sodium pentanolate
• 英文别名: sodium amylate；n-pentanol sodium-alkoxide；sodium pentylate；sodium 1-pentanolate；pentan-1-ol; sodium salt；sodium n-pentanolate；sodium;pentan-1-olate
• CAS: 1941-84-0
• 化学式: C₅H₁₁O*Na
• 分子量: 110.132
• InChiKey: WVROFDYCUUILSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.46
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2915900090

反应信息

• 作为反应物：
  描述：

  sodium pentanolate 在 dichlorophosphinylphosphorimidic trichloride 作用下， 以 戊醇 、 苯 为溶剂， 生成 (bis-pentyloxy-phosphoryl)-phosphorimidic acid tripentyl ester
  参考文献：
  名称：

  Synthesis of trialkyl (dialkoxyphosphorylimido)phosphates

  摘要：

  DOI：

  10.1007/bf00951012
• 作为产物：
  描述：

  戊醇 在 sodium 作用下， 生成 sodium pentanolate
  参考文献：
  名称：

  Method For Directly Producing Fine-Particle Diketopyrrolopyrrol Pigments

  摘要：

  该发明涉及一种直接生产精细颗粒1,4-二酮吡咯[3,4-c]吡咯的方法，其中R1a、R1b、R2a和R2b分别表示氢、卤素、C1-C4烷基、C1-C4烷氧基、氰基或苯基，所述化合物的最大频率分布在20至120纳米之间。根据该方法，腈与琥珀酸酯或内酰胺或烯胺在碱性介质中反应形成颜料盐，然后进行颜料碱盐的质子解离。该方法的特点在于在颜料碱盐的质子解离过程中添加有效量的式（II）的颜料分散剂。在式（II）中，Q是来自苯并吡喃、喹啉喹啉醌、蒽醌、吲哚醌、二氧化锌、二酮吡咯吡咯、靛蓝、硫靛蓝、噻吩靛蓝、异吲哚、异吲哚酮、吡喃蒽、异苯并吡啶颜料组中的有机颜料的基团。

  公开号：

  US20100121053A1
• 作为试剂：
  描述：

  戊醇 、 氰 在 sodium pentanolate 作用下， 生成 Oxaldiimidsaeuredi-n-pentylester
  参考文献：
  名称：

  Hartke,K.; Hoppe,H., Chemische Berichte, 1974, vol. 107, p. 3121 - 3129

  摘要：

  DOI：

文献信息

• Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
  申请人：——

  公开号：US20040077605A1

  公开（公告）日：2004-04-22

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及含有这种化合物的药物组合物。
• METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
  申请人：Salvati E. Mark

  公开号：US20050119228A1

  公开（公告）日：2005-06-02

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及含有这种化合物的药物组合物。
• Heterocyclic compounds
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US06329381B1

  公开（公告）日：2001-12-11

  The present invention relates to a heterocyclic compound of the following general formula (I): wherein X is sulfur atom, oxygen atom or —NR3— (R3 may form a heterocyclic ring or a substituted heterocyclic ring with R1 via the nitrogen atom), R1 is alkyl group, substituted alkyl group, aryl group, substituted aryl group, heterocyclic group or substituted heterocyclic group, and R2 is hydrogen atom, halogen atom etc.; or its pharmaceutically acceptable salt and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases comprising the compound (I) or its pharmaceutically acceptable salt as active ingredients.

  本发明涉及以下通式（I）的杂环化合物：其中X是硫原子、氧原子或—NR3—（R3可能通过氮原子与R1形成杂环环或取代杂环环），R1是烷基、取代烷基、芳基、取代芳基、杂环基或取代杂环基，R2是氢原子、卤原子等；或其药学上可接受的盐和干扰素诱导剂、抗病毒剂、抗癌剂和免疫性疾病治疗剂，包括化合物（I）或其药学上可接受的盐作为活性成分。
• Organic reactions in strong alkalis. Part V. Alkali fusion of epoxides and ethers
  作者：M. F. Ansell、I. S. Shepherd、B. C. L. Weedon

  DOI：10.1039/j39710001840

  日期：——

  The results obtained from the alkali fusion of long-chain epoxy-acids indicate the occurrence of at least four different reaction pathways, one of which, a β-elimination reaction, appears to be novel for unactivated epoxides. This particular reaction is also shown to occur with simple acylic ethers, as exemplified by 11-alkoxyundecanoic acids.

  从长链环氧酸的碱熔获得的结果表明，至少存在四种不同的反应途径，其中一种β-消除反应对于未活化的环氧化物似乎是新颖的。还显示该特定反应是用简单的酰基醚发生的，例如11-烷氧基十一烷酸。
• Studies on antitumor agents. V. Syntheses and antitumor activities of 5-fluorouracil derivatives.
  作者：JUNICHI YAMASHITA、ICHIRO YAMAWAKI、SHUICHI UEDA、MITSUGI YASUMOTO、NORIO UNEMI、SADAO HASHIMOTO

  DOI：10.1248/cpb.30.4258

  日期：——

  Six types of 5-fluorouracil (5-FU) derivatives were synthesized ; namely, 2, 4-di-O-substituted, 2-O-substituted, 4-O-substituted, 1, 3-disubstituted, 1-substituted and 3-substituted compounds. After oral administration of these compounds to rats, the blood levels of 5-FU were determined. Among O-substituted derivatives, a 4-O-substituted derivative was most easily activated to 5-FU and 2-O-substituted derivatives were next most easily activated. Among N-substituted derivatives, acyl and sulfonyl derivatives showed the highest 5-FU releasing abilities and 1-alkoxymethyl substituted derivatives showed low ability. N-Alkyl substituted derivatives were not activated to 5-FU. Several compounds which gave higher blood levels of 5-FU than that obtained with 1-(tetrahydro-2-furyl)-5-fluorouracil (Thf-FU), as well as same related compounds, were selected and their antitumor activities were examined. The 2-O-substituted derivatives, 2-butoxy-5-fluoro-4 (1H)-pyrimidone (11) and 2-benzyloxy-5-fluoro-4 (1H)-pyrimidone (19), were as effective as Thf-FU. The activities of 2, 4-di-O-substituted derivatives, 2, 4-dibutoxy-5-fluoropyrimidine (1) and 2, 4-dibenzyloxy-5-fluoropyrimidine (6), against Ehrlich carcinoma and against sarcoma 180, respectively, were the same as those of Thf-FU. The 1-substituted derivatives, 1-ethoxymethyl-5-fluorouracil (49) and 1-(1-ethoxy-1-phenylmethyl)-5-fluorouracil (50), were found to be as effective as Thf-FU.

  合成了六类氟尿嘧啶（5-FU）衍生物，即2,4-二-O-取代、2-O-取代、4-O-取代、1,3-二取代、1-取代和3-取代的化合物。在大鼠口服这些化合物后，测定了5-FU的血药浓度。在O-取代衍生物中，4-O-取代衍生物最容易被激活为5-FU，其次是2-O-取代衍生物。在N-取代衍生物中，酰基和磺酰基衍生物显示出最高的5-FU释放能力，1-烷氧甲基取代衍生物的释放能力较低。N-烷基取代衍生物未被激活为5-FU。选择了几种在血中5-FU水平高于1-(四氢-2-呋喃基)-5-氟尿嘧啶（Thf-FU）的化合物，以及一些相关化合物，并对其抗肿瘤活性进行了检测。2-O-取代衍生物，2-丁氧基-5-氟-4(1H)-嘧啶酮（11）和2-苄氧基-5-氟-4(1H)-嘧啶酮（19），与Thf-FU一样有效。2,4-二-O-取代衍生物，2,4-二丁氧基-5-氟嘧啶（1）和2,4-二苄氧基-5-氟嘧啶（6），对艾氏癌和肉瘤180的活性与Thf-FU相同。1-取代衍生物，1-乙氧甲基-5-氟尿嘧啶（49）和1-(1-乙氧基-1-苯甲基)-5-氟尿嘧啶（50），发现与Thf-FU一样有效。